RxDoctor Payments Data

Matthew Lewis, MD

Dermatology · Stanford, CANPI 1235454182

Payments from drug & device makers

$441,762in general payments, 2019–2025

Across 325 payments — averaging $1359.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$234K
  • Regeneron Healthcare Solutions, Inc.$127K
  • Galderma Laboratories, L.p.$62K
  • Sanofi$11K
  • Pfizer$6K
  • Gilead$2K
  • plus $1K from 1 others

What the payments were for

  • Consulting fees$11,6933%
  • Speaking & faculty fees$395,38890%
  • Travel & lodging$27,0236%
  • Food & beverage$7,5442%
  • Education$1160%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie190$233,516
Regeneron Healthcare Solutions, Inc.82$126,796
Galderma Laboratories, L.p.39$61,799
Sanofi6$10,604
Pfizer6$5,768
Gilead1$2,100
UCB, Inc.1$1,180

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$441,762 in reported general payments places this provider in the 95th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$118,323
Medicare patients
421
Services billed
1,397

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab130$563,923
Dupixent SyringeDupilumab142$526,103
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5036$454,012
Taltz AutoinjectorIxekizumab46$372,813
Gamunex-CImmune Globul G/Gly/Iga Avg 4627$338,663
Skyrizi PenRisankizumab-Rzaa15$301,888
Bimzelx AutoinjectorBimekizumab-Bkzx21$281,558
SkyriziRisankizumab-Rzaa13$247,252
RinvoqUpadacitinib19$135,074
Cosentyx (2 Syringes)Secukinumab15$99,587
Humira(Cf) PenAdalimumab14$96,257
XeljanzTofacitinib Citrate14$72,674
OtezlaApremilast11$49,917
Mycophenolate Mofetil44$25,771
QbrexzaGlycopyrronium Tosylate16$10,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSkyrizi, Rinvoq$233,516$382,32732 claims
PfizerXeljanz$5,768$72,67414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,875 dermatology providers in California.

Other dermatology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →